Share this page!

Vincent Rajkumar Profile picture
Twitter logo
4 Dec, 13 tweets, 13 min read
Here are selected abstracts from @MayoClinic @MayoCancerCare being presented at #ASH20

1. CyTOF and TNA seq studies reveal major defects in the cellular tumor immune microenvironment with refractory myeloma. ash.confex.com/ash/2020/webpr… @Taxkourel @myelomaMD @MayoMyeloma
2. Lab studies using salicylates to augment anti tumor effects of selinexor. #ASH20 ash.confex.com/ash/2020/webpr… @JithmaA
3. In patients needing Auto transplant for relapsed DLBCL, interestingly the GCB type had poorer outcome compared to non GCB. #ASH20 ash.confex.com/ash/2020/webpr… @MadihaIqbal13
4. Clonal somatic mutations associated with poorer survival in DLBCL. #ASH20 ash.confex.com/ash/2020/webpr… @MaurerStats
5. “(Quality of life) in survivors of aggressive lymphomas is higher than the United States general population at 1, 2, 3, 6, and 9 years after diagnosis.” Amazing. #ASH20 @CaThompsonMD @GitaThanaMD ash.confex.com/ash/2020/webpr…
6. CA-4948, IRAK4 inhibitor: phase I results in mantle cell lymphoma. #ASH20 ash.confex.com/ash/2020/webpr…
7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20 @MayoMyeloma ash.confex.com/ash/2020/webpr…
8. Results of CAR-T therapy for lymphoma @MayoClinic @MayoCancerCare #ASH20 ash.confex.com/ash/2020/webpr… @CaThompsonMD
9. Results of CAR-T therapy with Ide-cel, a BCMA-directed CAR T in myeloma. #ASH20 @MayoMyeloma ash.confex.com/ash/2020/webpr…
10. Lummicar-2: A Phase 1b/2 BCMA CAR T trial results in Patients with Relapsed and/or Refractory Myeloma. #ASH20 @myelomaMD @MayoMyeloma ash.confex.com/ash/2020/webpr…
11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rate in heavily pretreated patients. Need to add this to my table below! #ASH20 @myelomaMD @MayoMyeloma ash.confex.com/ash/2020/webpr…
12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20 @MayoMyeloma @myelomaMD ash.confex.com/ash/2020/webpr…
13. I’m thrilled that my colleagues @n_gangat and Ayalew Tefferi @MayoClinic @MayoCancerCare are coauthors on the Plenary Session Presentation on loss of LKB1/STK11 and leukemic progression in myeloproliferative neoplasms. #ASH20 ash.confex.com/ash/2020/webpr…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Vincent Rajkumar

Vincent Rajkumar Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VincentRK

Vincent Rajkumar Profile picture
5 Dec
@sumanthraman @EricTopol This is a great question. I’ll try my best to answer.
1) First is that the question also applies to Europe which is doing just as bad as the US. So why are USA and Europe doing worse than more crowded and much poorer countries? ImageImage
@sumanthraman @EricTopol 2) I think one of the most likely factors is that there must be some form of pre-existing cross reactive immunity which is helping keep the disease severity low. So more asymptomatic cases, and fewer hospitalizations and deaths. I did a thread on this a while back.
@sumanthraman @EricTopol 3) The second factor is certain favorable demographics in countries like India: age distribution (lower median age), and lower prevalence of obesity. A lot of severe COVID is associated with these two factors.
Read 6 tweets
Vincent Rajkumar Profile picture
3 Dec
One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do it?

The update of the IFM trial at #ASH20 addresses this question. ash.confex.com/ash/2020/webpr… #ASH20VR

Thread 👇
1) Should eligible patients do a transplant: Yes

Two RCTs show an Overall Survival benefit of transplant over chemo alone.

2) Does timing early vs delayed matter?

4 RCTs (including IFM 2009) show similar overall survival regardless of when transplant is done (early vs delayed)
The IFM 2009 results show identical overall survival ~60% at 8 years with early or delayed transplant, even though not everyone who is in the delayed transplant group even gets to a transplant. But there are important caveats.
Read 7 tweets
Vincent Rajkumar Profile picture
3 Dec
Follow and search #ASH20VR for my commentaries (&critiques) on important myeloma related abstracts during #ASH20.

I have used these personal hashtags selectively to avoid information overload. Check #ASH19VR for last years picks. @MyelomaTeacher @NorthTxMSG @grpetersen1
I started doing personal hashtags at meetings a few years ago for my own selfish reasons. It has worked out great for me. And I’m hoping it’s useful for others.
I tweet a lot at ASH and other Hematology/oncology meetings but won’t add my personal hashtag unless I feel like it’s something very important that I would want to look up in the future.
Read 4 tweets
Vincent Rajkumar Profile picture
1 Dec
Should we screen for myeloma in high risk individuals?

For Blacks with one or more affected first-degree relatives, & all others with 2 or more affected first-degree relatives — Yes.

I’ve come to this conclusion after considering pros & cons. @nature nature.com/articles/d4158…
If you are going to offer screening, I suggest only a one-time year at age 50 and older, or 10 years before diagnosis in first degree relative.

Test: SPEP, Serum IFE, and Serum FLC. We are not screening for MGUS, but for evidence suggestive of high risk SMM or MM.
This recommendation affects a small number of people who are at high risk of developing SMM or MM. For all others, including general population, wait till results of iSTOP MM RCT, and other studies such as PROMISE. @sykristinsson @IreneGhobrial
Read 4 tweets
Vincent Rajkumar Profile picture
23 Nov
3 for 3!

@AstraZeneca @UniofOxford vaccine highly effective against COVID. Lower cost, easier storage & transport. This is also the vaccine that @SerumInstIndia is manufacturing: means great news for India. @nramind @rameshlaus @sumanthraman @DrEricDing nytimes.com/live/2020/11/2…
This comes on the heels of great results from @pfizer and @moderna_tx

With the pandemic affecting the whole world, we need all the vaccines we can get. I’m very pleased with the efficacy. I wouldn’t worry about 70% versus 95%. Efficacy is efficacy. @singersrinivas @ShirleySetia
The @UniofOxford @AstraZeneca vaccine is an adenovirus vector vaccine. See mechanism of action and doses reserved by country. @business @PSampathkumarMD 👇
Read 7 tweets
Vincent Rajkumar Profile picture
13 Nov
Here are my Top 5 #ASH20 @ASH_hematology myeloma abstracts. #ASH20VR
I’ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @szusmani @ninashah33 @profghjackson @Phari @PerrotAurore @mvmateos
Thread for countdown👇
#5 Allogeneic off-the-shelf CAR-T therapy for myeloma. First in human results with Anti BCMA ALLO-647 shows clinical activity in myeloma.
5 of 15 responses. #ASH20 #ASH20VR @sloan_kettering @Phari @AllogeneTx ash.confex.com/ash/2020/webpr…
#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA locus at 16p. Important work. #ASH20 #ASH20VR @DanaFarber @NoopurRajeMD

ash.confex.com/ash/2020/webpr…
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @VincentRK has new unrolls!

Check out other threads from @VincentRK!

Read all threads by @VincentRK